Enjoy complimentary customisation on priority with our Enterprise License!
The global plasma fractionation market size is estimated to grow by USD 10.00 billion at a CAGR of 6.09% between 2023 and 2028.
The plasma industry witnesses growth with a specialized plasma therapy manufacturing facility producing immunoglobulins and albumins for therapeutic areas like respiratory diseases and liver diseases. AATD (Alpha-1-antitrypsin deficiency) and chronic obstructive pulmonary disease (COPD) are targeted, along with rare diseases and chronic disorders. Blood plasma, collected at plasma collection centers, undergoes plasma fractionation to yield essential components like anticoagulant factors and prothrombin complex. Primary immunodeficiency conditions benefit from subcutaneous immunoglobulin (SCIG) treatments. This comprehensive approach supports patients suffering from emphysema and other lung diseases, underscoring the vital role of plasma therapy in managing diverse medical conditions.
1 Executive Summary
2 Market Landscape
3 Market Sizing
4 Historic Market Size
5 Five Forces Analysis
6 Market Segmentation by Product
7 Market Segmentation by Application
8 Customer Landscape
9 Geographic Landscape
10 Drivers, Challenges, and Trends
11 Vendor Landscape
12 Vendor Analysis
13 Appendix
Get lifetime access to our
Technavio Insights
Quick Report Overview:
Cookie Policy
The Site uses cookies to record users' preferences in relation to the functionality of accessibility. We, our Affiliates, and our Vendors may store and access cookies on a device, and process personal data including unique identifiers sent by a device, to personalise content, tailor, and report on advertising and to analyse our traffic. By clicking “I’m fine with this”, you are allowing the use of these cookies. Please refer to the help guide of your browser for further information on cookies, including how to disable them. Review our Privacy & Cookie Notice.